The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: Implications for therapy in p53-defective CLL patients

J. Boysen; S. Sinha; T. Price-Troska; S. L. Warner; D. J. Bearss; D. Viswanatha; T. D. Shanafelt; N. E. Kay; A. K. Ghosh

doi:10.1038/leu.2013.298

The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: Implications for therapy in p53-defective CLL patients

J. Boysen, S. Sinha, T. Price-Troska, S. L. Warner, D. J. Bearss, D. Viswanatha, T. D. Shanafelt, N. E. Kay, A. K. Ghosh

Hematology

Research output: Contribution to journal › Letter › peer-review

31 Scopus citations

Original language	English (US)
Pages (from-to)	451-455
Number of pages	5
Journal	Leukemia
Volume	28
Issue number	2
DOIs	https://doi.org/10.1038/leu.2013.298
State	Published - Feb 2014

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/leu.2013.298

Cite this

@article{8b3f7e3458c84aa791ec73d1047525d6,

title = "The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: Implications for therapy in p53-defective CLL patients",

author = "J. Boysen and S. Sinha and T. Price-Troska and Warner, {S. L.} and Bearss, {D. J.} and D. Viswanatha and Shanafelt, {T. D.} and Kay, {N. E.} and Ghosh, {A. K.}",

note = "Funding Information: This work was supported, in part, by a Mayo Clinic Hematology Research Award 2012, Eagles Cancer Research Award and research fund from National Cancer Institute CA170006-01A1 to AKG and research fund from National Cancer Institute CA95241 to NEK. We also acknowledge Tolero for providing us with the Axl inhibitor SGI-7079 and excellent secretarial help from Ms Tammy Hughes.",

year = "2014",

month = feb,

doi = "10.1038/leu.2013.298",

language = "English (US)",

volume = "28",

pages = "451--455",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia

T2 - Implications for therapy in p53-defective CLL patients

AU - Boysen, J.

AU - Sinha, S.

AU - Price-Troska, T.

AU - Warner, S. L.

AU - Bearss, D. J.

AU - Viswanatha, D.

AU - Shanafelt, T. D.

AU - Kay, N. E.

AU - Ghosh, A. K.

N1 - Funding Information: This work was supported, in part, by a Mayo Clinic Hematology Research Award 2012, Eagles Cancer Research Award and research fund from National Cancer Institute CA170006-01A1 to AKG and research fund from National Cancer Institute CA95241 to NEK. We also acknowledge Tolero for providing us with the Axl inhibitor SGI-7079 and excellent secretarial help from Ms Tammy Hughes.

PY - 2014/2

Y1 - 2014/2

UR - http://www.scopus.com/inward/record.url?scp=84893767856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893767856&partnerID=8YFLogxK

U2 - 10.1038/leu.2013.298

DO - 10.1038/leu.2013.298

M3 - Letter

C2 - 24217154

AN - SCOPUS:84893767856

SN - 0887-6924

VL - 28

SP - 451

EP - 455

JO - Leukemia

JF - Leukemia

IS - 2

ER -

The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: Implications for therapy in p53-defective CLL patients

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this